New immunosuppressive agents and risk for invasive fungal infections

Georg Maschmeyer, Thomas F. Patterson

Research output: Contribution to journalShort surveypeer-review

11 Scopus citations


Increased numbers of invasive fungal infections (IFI) were reported in patients treated with newer immunosuppressive drugs such as tumor necrosis factor (TNF)-α antagonists, the anti-CD52 antibody alemtuzumab, or the interleukin-2 receptor antibody basiliximab. These drugs are administered to patients who have autoimmune inflammatory diseases and lymphoid malignancies, or are recipients of solid organ or allogeneic hematopoietic stem cell transplants. IFI risk is higher in patients receiving TNF-α blockers or alemtuzumab late in the course of disease and in those with a history of IFI. Incidence and mortality rates of IFI are confounded by frequent, multiple comedications, heterogeneous definitions for IFI, and a presumed reporting bias. For filamentous molds and endemic fungal infections, different regional prevalence rates must be considered. Generally, invasive infections are more frequent among these groups and thus are important considerations in the management of patients receiving these immunosuppressive drugs.

Original languageEnglish (US)
Pages (from-to)435-438
Number of pages4
JournalCurrent Infectious Disease Reports
Issue number6
StatePublished - Nov 2009
Externally publishedYes

ASJC Scopus subject areas

  • Infectious Diseases


Dive into the research topics of 'New immunosuppressive agents and risk for invasive fungal infections'. Together they form a unique fingerprint.

Cite this